Dexamethasone-mediated oncogenicity in vitro and in an animal model of glioblastoma

Abstract

OBJECTIVE Dexamethasone, a known regulator of mesenchymal programming in glioblastoma (GBM), is routinely used to manage edema in GBM patients. Dexamethasone also activates the expression of genes, such as CEBPB, in GBM stem cells (GSCs). However, the drug's impact on invasion, proliferation, and angiogenesis in GBM remains unclear. To determine whether dexamethasone induces invasion, proliferation, and angiogenesis in GBM, the authors investigated the drug's impact in vitro, in vivo, and in clinical information derived from The Cancer Genome Atlas (TCGA) cohort. METHODS Expression profiles of patients from the TCGA cohort with mesenchymal GBM (n = 155) were compared with patients with proneural GBM by comparative marker selection. To obtain robust data, GSCs with IDH1 wild-type (GSC3) and with IDH1 mutant (GSC6) status were exposed to dexamethasone in vitro and in vivo and analyzed for invasion (Boyden chamber, human-specific nucleolin), proliferation (Ki-67), and angiogenesis (CD31). Ex vivo tumor cells from dexamethasone-treated and control mice were isolated by fluorescence activated cell sorting and profiled using Affymetrix chips for mRNA (HTA 2.0) and microRNAs (miRNA 4.0). A pathway analysis was performed to identify a dexamethasone-regulated gene signature, and its relationship with overall survival (OS) was assessed using Kaplan-Meier analysis in the entire GBM TCGA cohort (n = 520). RESULTS The mesenchymal subgroup, when compared with the proneural subgroup, had significant upregulation of a dexamethasone-regulated gene network, as well as canonical pathways of proliferation, invasion, and angiogenesis. Dexamethasone-treated GSC3 demonstrated a significant increase in invasion, both in vitro and in vivo, whereas GSC6 demonstrated a modest increase. Furthermore, dexamethasone treatment of both GSC3 and GSC6 lines resulted in significantly elevated cell proliferation and angiogenesis in vivo. Patients with mesenchymal GBM had significant upregulation of dexamethasone-regulated pathways when compared with patients with proneural GBM. A prognostic (p = 0.0007) 33-gene signature was derived from the ex vivo expression profile analyses and used to dichotomize the entire TCGA cohort by high (median OS 12.65 months) or low (median OS 14.91 months) dexamethasone signature. CONCLUSIONS The authors present evidence that furthers the understanding of the complex effects of dexamethasone on biological characteristics of GBM. The results suggest that the drug increases invasion, proliferation, and angiogenesis in human GSC-derived orthotopic tumors, potentially worsening GBM patients' prognoses. The authors believe that careful investigation is needed to determine how to minimize these deleterious dexamethasone-associated side effects in GBM.

Dexamethasone in Glioblastoma Multiforme Therapy: Mechanisms and Controversies

“…DEX significantly increased the invasive properties of the GSC3 cell line, both in vitro and in vivo . Moreover, using both GSC3 and GSC6 lines, the drug promoted proliferation and angiogenesis, in vivo (Luedi et al, 2018). The results of this interesting study, have questioned the use of DEX in GBM therapy, highlighting its ability to increase the aggressiveness of the tumor.…”

Dexamethasone Interferes with Autophagy and Affects Cell Survival in Irradiated Malignant Glioma Cells

“…In a retrospective clinical study, the administration of dexamethasone during concomitant chemoradiotherapy with temozolomide resulted in poor prognosis in newly diagnosed GBM patients 30) . Recently, Luedi et al 20) observed the effect of dexamethasone in patient-derived GBM stem cells. They found that when exposure to dexamethasone, isocitrate dehydrogenase 1 (IDH1) wild-type cells (typical of primary GBM) showed significantly higher invasion, cell proliferation, and angiogenesis than IDH1 mutant-type GBM stem cells.…”

Asymmetrical 3D Nanoceria Channel for Severe Neurological Defect Regeneration

“…In this study, we analyzed the angiogenic potential of nanoceria in long-range nerve defect in vivo for the first time. We included CD31 and CD34, two markers for angiogenesis (Luedi et al., 2018, Wang et al., 2017). The neovascularization was assessed upon several indicators, including microvessel density (MVD), vessel-like structure (VLS) area, and density ((VLS area+ CD31/CD34+ area)/total scaffold area) at 6, 12, and 18 weeks after surgery.…”